Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients

Wen Ying Lee, Helen H.W Chen, Nan-Haw Chow, Wu-Chou Su, Pin Wen Lin, How-Ran Guo

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Purpose: RON and MET belong to a subfamily of tyrosine kinase receptors. They both can induce invasive growth, including migration, cell dissociation, and matrix invasion. Cross-linking experiments show that RON and MET form a noncovalent complex on the cell surface and cooperate in intracellular signaling. We wanted to examine the clinical significance of RON and MET expression patterns in node-negative breast cancer. Experimental Design: We studied the protein expressions of RON and MET in five breast cancer cell lines and a homogeneous cohort of 103 T1-2N0M0 breast carcinoma patients, including 52 patients with distant metastases and 51 patients with no evidence of disease after at least a 10-year follow-up. Results: Both HCC1937 and MDA-MB-231 cancer cell lines co-overexpressed RON and MET. The MCF-7 cell line did not express RON or MET. In multiple logistic regression analysis, RON expression (odds ratio, 2.6; P = 0.05) and MET expression (odds ratio, 4.7; P = 0.009) were independent predictors of distant relapse. RON+/MET+ and RON-/MET+ tumors resulted in a large risk increase for 10-year disease-free survival after adjusting for tumor size, histologic grade, estrogen receptor, bcl-2, HER-2/neu, and p53 status by multivariate Cox analysis (risk ratio, 5.3; P = 0.001 and risk ratio, 3.76; P = 0.005). The 10-year disease-free survival was 79.3% in patients with RON-/MET- tumors, was only 11.8% in patients with RON+/MET+ tumors, and was 43.9% and 55.6% in patients with RON-/MET+ and RON+/MET- tumors. Conclusions: Co-expression of RON and MET seems to signify an aggressive phenotype in node-negative breast cancer patients.

Original languageEnglish
Pages (from-to)2222-2228
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number6
DOIs
Publication statusPublished - 2005 Mar 15

Fingerprint

Breast Neoplasms
Odds Ratio
Neoplasms
Cell Line
rice bran saccharide
Disease-Free Survival
Estrogen Receptor beta
MCF-7 Cells
Receptor Protein-Tyrosine Kinases
Cell Movement
Research Design
Multivariate Analysis
Logistic Models
Regression Analysis
Neoplasm Metastasis
Phenotype
Recurrence
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{2f7ca8779dc246dbb9f2e6c00716cd0b,
title = "Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients",
abstract = "Purpose: RON and MET belong to a subfamily of tyrosine kinase receptors. They both can induce invasive growth, including migration, cell dissociation, and matrix invasion. Cross-linking experiments show that RON and MET form a noncovalent complex on the cell surface and cooperate in intracellular signaling. We wanted to examine the clinical significance of RON and MET expression patterns in node-negative breast cancer. Experimental Design: We studied the protein expressions of RON and MET in five breast cancer cell lines and a homogeneous cohort of 103 T1-2N0M0 breast carcinoma patients, including 52 patients with distant metastases and 51 patients with no evidence of disease after at least a 10-year follow-up. Results: Both HCC1937 and MDA-MB-231 cancer cell lines co-overexpressed RON and MET. The MCF-7 cell line did not express RON or MET. In multiple logistic regression analysis, RON expression (odds ratio, 2.6; P = 0.05) and MET expression (odds ratio, 4.7; P = 0.009) were independent predictors of distant relapse. RON+/MET+ and RON-/MET+ tumors resulted in a large risk increase for 10-year disease-free survival after adjusting for tumor size, histologic grade, estrogen receptor, bcl-2, HER-2/neu, and p53 status by multivariate Cox analysis (risk ratio, 5.3; P = 0.001 and risk ratio, 3.76; P = 0.005). The 10-year disease-free survival was 79.3{\%} in patients with RON-/MET- tumors, was only 11.8{\%} in patients with RON+/MET+ tumors, and was 43.9{\%} and 55.6{\%} in patients with RON-/MET+ and RON+/MET- tumors. Conclusions: Co-expression of RON and MET seems to signify an aggressive phenotype in node-negative breast cancer patients.",
author = "Lee, {Wen Ying} and Chen, {Helen H.W} and Nan-Haw Chow and Wu-Chou Su and Lin, {Pin Wen} and How-Ran Guo",
year = "2005",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1761",
language = "English",
volume = "11",
pages = "2222--2228",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. / Lee, Wen Ying; Chen, Helen H.W; Chow, Nan-Haw; Su, Wu-Chou; Lin, Pin Wen; Guo, How-Ran.

In: Clinical Cancer Research, Vol. 11, No. 6, 15.03.2005, p. 2222-2228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients

AU - Lee, Wen Ying

AU - Chen, Helen H.W

AU - Chow, Nan-Haw

AU - Su, Wu-Chou

AU - Lin, Pin Wen

AU - Guo, How-Ran

PY - 2005/3/15

Y1 - 2005/3/15

N2 - Purpose: RON and MET belong to a subfamily of tyrosine kinase receptors. They both can induce invasive growth, including migration, cell dissociation, and matrix invasion. Cross-linking experiments show that RON and MET form a noncovalent complex on the cell surface and cooperate in intracellular signaling. We wanted to examine the clinical significance of RON and MET expression patterns in node-negative breast cancer. Experimental Design: We studied the protein expressions of RON and MET in five breast cancer cell lines and a homogeneous cohort of 103 T1-2N0M0 breast carcinoma patients, including 52 patients with distant metastases and 51 patients with no evidence of disease after at least a 10-year follow-up. Results: Both HCC1937 and MDA-MB-231 cancer cell lines co-overexpressed RON and MET. The MCF-7 cell line did not express RON or MET. In multiple logistic regression analysis, RON expression (odds ratio, 2.6; P = 0.05) and MET expression (odds ratio, 4.7; P = 0.009) were independent predictors of distant relapse. RON+/MET+ and RON-/MET+ tumors resulted in a large risk increase for 10-year disease-free survival after adjusting for tumor size, histologic grade, estrogen receptor, bcl-2, HER-2/neu, and p53 status by multivariate Cox analysis (risk ratio, 5.3; P = 0.001 and risk ratio, 3.76; P = 0.005). The 10-year disease-free survival was 79.3% in patients with RON-/MET- tumors, was only 11.8% in patients with RON+/MET+ tumors, and was 43.9% and 55.6% in patients with RON-/MET+ and RON+/MET- tumors. Conclusions: Co-expression of RON and MET seems to signify an aggressive phenotype in node-negative breast cancer patients.

AB - Purpose: RON and MET belong to a subfamily of tyrosine kinase receptors. They both can induce invasive growth, including migration, cell dissociation, and matrix invasion. Cross-linking experiments show that RON and MET form a noncovalent complex on the cell surface and cooperate in intracellular signaling. We wanted to examine the clinical significance of RON and MET expression patterns in node-negative breast cancer. Experimental Design: We studied the protein expressions of RON and MET in five breast cancer cell lines and a homogeneous cohort of 103 T1-2N0M0 breast carcinoma patients, including 52 patients with distant metastases and 51 patients with no evidence of disease after at least a 10-year follow-up. Results: Both HCC1937 and MDA-MB-231 cancer cell lines co-overexpressed RON and MET. The MCF-7 cell line did not express RON or MET. In multiple logistic regression analysis, RON expression (odds ratio, 2.6; P = 0.05) and MET expression (odds ratio, 4.7; P = 0.009) were independent predictors of distant relapse. RON+/MET+ and RON-/MET+ tumors resulted in a large risk increase for 10-year disease-free survival after adjusting for tumor size, histologic grade, estrogen receptor, bcl-2, HER-2/neu, and p53 status by multivariate Cox analysis (risk ratio, 5.3; P = 0.001 and risk ratio, 3.76; P = 0.005). The 10-year disease-free survival was 79.3% in patients with RON-/MET- tumors, was only 11.8% in patients with RON+/MET+ tumors, and was 43.9% and 55.6% in patients with RON-/MET+ and RON+/MET- tumors. Conclusions: Co-expression of RON and MET seems to signify an aggressive phenotype in node-negative breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=16844363750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844363750&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1761

DO - 10.1158/1078-0432.CCR-04-1761

M3 - Article

C2 - 15788670

AN - SCOPUS:16844363750

VL - 11

SP - 2222

EP - 2228

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -